View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
February 7, 2022

Long Covid may loom for Omicron patients

Even mild cases of Covid-19 can cause long Covid, but there are no data indicating the Omicron variant increases the chance of it.

By GlobalData Healthcare

As the latest Covid-19 Omicron surge starts to recede, there could be a spike in the number of patients affected by long Covid, the persistence over a period of 12 weeks or more of physical and neuropathic symptoms. There is evidence that about 14–30% of people with Covid-19 will go on to experience long Covid, which includes symptoms such as fatigue, shortness of breath, fevers, gastrointestinal issues, sleep disorders, ‘brain fog’, anxiety, post-traumatic stress disorder (PTSD) and depression. These patients could be burdened with these symptoms for months to years, though we do not know if the burden is the same for the Omicron variant as it is for the previous variants.

The Omicron variant often results in a milder disease outcome. Despite this, mild cases of Covid-19 can lead to long Covid and the majority of long Covid patients had a mild infection, though this could be due to there being more mild cases of Covid-19 than severe cases. Prolonged symptoms can also develop after asymptomatic Covid-19. There are currently no data that indicate the Omicron variant increases the chance of symptoms persisting.

There is some evidence that vaccinations can reduce the chance of developing persistent symptoms in the case of breakthrough infections. Mobile application data from a study of UK adults indicated that around 11% of unvaccinated patients had lingering symptoms for at least 28 days, compared with 5% of vaccinated individuals. This risk reduction of more than one half is promising as the number of vaccinated individuals has increased to more than four billion, according to GlobalData’s Coronavirus Disease 2019 Epidemiology Dashboard. Vaccines could help reduce these long-term care costs for Covid-19 patients.

Understanding the mechanism of long Covid will prove crucial to helping treat these patients. A recent study by the New South Wales Kirby Institute has indicated that the disease may be caused by sustained inflammation and activation of the immune system, which can last for at least eight months after the initial infection. The researchers detected six proinflammatory cytokines involved in the innate immune response that were elevated in long Covid patients. This knowledge could help provide paths to treating and diagnosing prolonged symptoms, which could bring some relief to patients suffering from them.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU